Bcl-2 Inhibitor TQB3909 clinical trials
How each study uses Bcl-2 Inhibitor TQB3909 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Bcl-2 Inhibitor TQB3909 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- TQB3909 tablets
- 6
Studies by the year they started
8 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Bcl-2 Inhibitor TQB3909 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Not yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07753369Written as TQB3909 Tablets
- A Clinical Trial of TQB3909 Tablets in Combination With Azacitidine for the Treatment of Myeloid MalignanciesRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07011186Written as TQB3909 Tablets + Azacitidine
- A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic MalignancyNot yet recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06211751Written as TQB3909 tablets
- A Study to Evaluate Drug-Drug Interaction of TQB3909 TabletsNot yet recruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06165822Written as TQB3909 tablets
- A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) .RecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05959694Written as TQB3909 tablet
- A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)TerminatedPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06245941Written as TQB3909 tablets
- A Clinical Trial of TQB3909 Tablets in Patients With Breast CancerStatus unknownPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05775575Written as TQB3909 tablets
- A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant TumorsStatus unknownPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04975204Written as TQB3909 Tablets